Comment: Economic Impact of Therapeutic Substitution of a Brand Selective Serotonin Reuptake Inhibitor with an Alternative Generic Selective Serotonin Reuptake Inhibitor in Patients with Major Depressive Disorder
Restricted accessResearch articleFirst published online September, 2011
Comment: Economic Impact of Therapeutic Substitution of a Brand Selective Serotonin Reuptake Inhibitor with an Alternative Generic Selective Serotonin Reuptake Inhibitor in Patients with Major Depressive Disorder
WuEQ, YuAP, LauzonV. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother2011; 45:441–51. DOI 10.1345/aph.1P482
2.
MorrisKJ. Strategies for acquiring affordable medications for seniors. Nurs Clin North Am2005; 40:51–62.
3.
PolinskiJM, KilabukE, SchneeweissS, BrennanT, ShrankWH. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc2010; 58:1764–79.
4.
VlahiotisA, DevineST, EichholzJ, KautznerA. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm2011; 17:123–32.
5.
OlfsonM, MarcusSC, TedescM, WanGJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry2006; 163:101–8.
6.
TurnerMS, MayDB, ArthurRR, XiongGL. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med2007; 261:205–13.
7.
GagneJJ, AvomJ, ShrankWH, SchneeweissS. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther2010; 88:347–53.
8.
López-CasasnovasG, Puig-JunoyJ. Review of the literature on reference pricing. Health Pol2001; 54:87–123.
9.
Ioannides-DemosLL, IbrahimJE, McNeilJJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilization and health outcomes. Pharmacoeconomics2002; 20:577–91.
